Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy Treatment
09 mars 2020 08h13 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, March 09, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236)...
Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering
05 mars 2020 08h15 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced...
Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea
03 mars 2020 08h53 HE
|
Enlivex Therapeutics Ltd
Regarding Submission of Proposal to the Korean Authorities for Potential Use of AllocetraTM as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU Nes-Ziona, Israel,...
Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
02 mars 2020 08h00 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements...
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
26 févr. 2020 13h45 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced...
Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering
24 févr. 2020 13h54 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements...
Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
24 févr. 2020 06h30 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its...
Data On Enlivex’s Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida
20 févr. 2020 08h37 HE
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a...
Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares
21 nov. 2019 07h30 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (“Enlivex” or the “Company”) (NASDAQ: ENLV) today announced that it has withdrawn its previously announced proposed...
Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares
20 nov. 2019 16h14 HE
|
Enlivex Therapeutics Ltd
Nes Ziona, Israel, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (“Enlivex” or the “Company”) (NASDAQ:ENLV) today announced that, subject to market and other conditions, it intends to...